RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Cohen, N. T., Cross, J. H., Arzimanoglou, A., Berkovic, S. F., Kerrigan, J. F., Miller, I. P., Webster, E., Soeby, L., Cukiert, A., Hesdorffer, D. K., Kroner, B. L., Saper, C. B., Schulze-Bonhage, A., Gaillard, W. D., & Hypothalamic Hamartoma writing group (2021). Hypothalamic hamartomas: Evolving understanding and management. Neurology, 97(18), 864-873. https://doi.org/10.1212/wnl.0000000000012773
Hypothalamic hamartomas (HH) are rare, basilar developmental lesions with widespread comorbidities often associated with refractory epilepsy and encephalopathy. Imaging advances allow for early, even prenatal, detection. Genetic studies suggest mutations in GLI3 and other patterning genes are involved in HH pathogenesis. About 50-80% of children with HH suffer from severe rage and aggression and a majority of cases exhibit externalizing disorders. Behavioral disruption and intellectual disability may predate epilepsy. Neuropsychological, sleep and endocrine disorders are typical. The purpose of this paper is to provide a summary of the current understanding of HH, and to highlight opportunities for future research.
